Ser347

Site Information
rGVssEssGDREkDS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 7831699

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	cervical cancer ( 1 ) , cervical adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	HeLa S3 (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 2 )

Upstream Regulation
Treatments:	nocodazole ( 1 )

References
1	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
2	Moritz A (2009) CST Curation Set: 7933; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
3	Gu T (2007) CST Curation Set: 2234; Year: 2007; Biosample/Treatment: cell line, RSK2-1/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info